Innova Captab: Business Overview & Financial Analysis
Innova Captab is an Indian pharmaceutical enterprise headquartered in Mumbai, Maharashtra. Promoted by Manoj Kumar Lohariwala and Vinay Kumar Lohariwala, the company operates across contract development and manufacturing organization (CDMO) services, domestic branded generic formulations, and international export markets. Operating manufacturing facilities in Baddi, Himachal Pradesh, and Jammu, Jammu & Kashmir, the enterprise supplies pharmaceutical brand owners and international distributor networks.
Segment Revenue Mix of Innova Captab (Q1 FY2027)
Innova Captab structures its business operations across CDMO services, domestic branded formulations, and international exports.
- CDMO Business Share – 68.2% of Total Revenue (Rs 205.80 crore)
- Domestic Branded Formulations Share – 21.5% of Total Revenue (Rs 64.80 crore)
- International Exports Share – 10.3% of Total Revenue (Rs 31.10 crore)
- Total Consolidated Revenue from Operations (Q1 FY2027) – Rs 301.70 crore (+12.8% YoY)
Contract development and manufacturing services serve as the primary revenue engine, providing formulation supply to top Indian pharmaceutical brand owners. Branded formulations and international exports supply generic markets across Asia, Africa, and Latin America.
Product Portfolio & Dosage Formats of Innova Captab (FY2026)
The enterprise manages a product portfolio spanning oral solids, liquids, dry syrups, injectables, and cephalosporin formulations.
- Product Catalog Scale – 600+ active commercial formulation SKUs
- Core Dosage Formats – Tablets, capsules, dry syrups, liquid orals, and cephalosporin injectables
- Key Therapeutic Categories – Anti-infectives, analgesics, cardiovascular, respiratory, and gastroenterology
- Commercial CDMO Client Base – 150+ pharmaceutical brand owners including Cipla, Mankind, and Zydus
Managing 600+ active formulation SKUs supports long-term contract manufacturing partnerships with leading Indian pharmaceutical enterprises. Diversifying across 150+ commercial CDMO clients limits revenue concentration risks.
Manufacturing Infrastructure & Facilities Scale of Innova Captab (Q1 FY2027)
Innova Captab operates formulation plants equipped with high-speed tableting, encapsulation, and dry powder filling lines.
- Total Operational Manufacturing Facilities Base – 3 manufacturing complexes in Baddi and Jammu
- Baddi Facility 1 & 2 Scale – 4.0+ billion tablets and 0.8+ billion capsules per annum
- Greenfield Jammu Facility Scale – Integrated oral solid dosage (OSD) and dry powder injectable unit
- Regulatory Approvals Held – WHO-GMP, EU-GMP compliant design, and ISO certifications
Operating 3 manufacturing complexes across Himachal Pradesh and Jammu gives Innova Captab a production capacity exceeding 4.8 billion oral solid units annually. Commissioning the greenfield Jammu facility expands production scale for domestic and export CDMO contracts.
Latest Quarterly Financial Performance of Innova Captab (Q1 FY2027)
Innova Captab recorded double-digit top-line turnover growth and profit expansion during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 301.70 crore (+12.8% YoY vs Rs 267.40 crore in Q1 FY2026)
- Consolidated Operating EBITDA – Rs 42.80 crore (+16.3% YoY vs Rs 36.80 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 14.19% (+43 bps YoY vs 13.76%)
- Consolidated Net Profit After Tax (PAT) – Rs 26.50 crore (+21.4% YoY vs Rs 21.80 crore in Q1 FY2026)
- Standalone Net Profit After Tax (PAT) – Rs 24.20 crore
First-quarter consolidated operating revenue expanded 12.8% year-on-year to Rs 301.70 crore, supported by higher CDMO dispatch volumes. Consolidated Net Profit After Tax rose 21.4% to Rs 26.50 crore, while operating EBITDA margins expanded to 14.19%.
Consolidated Annual Financial Performance of Innova Captab (FY2026)
The company achieved full-year turnover growth and cash flow conversion during full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 1,180.50 crore (+14.2% YoY)
- Full Year Consolidated Operating EBITDA – Rs 168.20 crore (+16.5% YoY)
- Full Year Operating EBITDA Margin – 14.25%
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 102.40 crore (+18.2% YoY)
- Return on Capital Employed (ROCE) Realisation – 16.80%
- Return on Equity (ROE) Realisation – 14.50%
Full-year operating turnover crossed Rs 1,180.00 crore in FY2026, as consolidated Net Profit After Tax reached Rs 102.40 crore. Delivering a return on capital employed of 16.80% reflects asset utilization across manufacturing facilities.
Balance Sheet Structure & Financial Health Ratios of Innova Captab (Q1 FY2027)
Innova Captab maintains a capital structure supported by equity net worth and managed debt gearing following its IPO.
- • Net Financial Debt to Equity Ratio – 0.28x (Post-IPO conservative leverage profile)
- • Total Consolidated Net Worth Base – ~Rs 920.00 crore
- • Working Capital Conversion Cycle – 72 days
- • Credit Rating Profile – Reaffirmed '[ICRA] A+ (Stable)'
Operating with a net debt-to-equity ratio of 0.28x provides balance sheet flexibility to execute capital expenditure plans. Credit rating agencies reaffirmed long-term ratings at '[ICRA] A+ (Stable)', confirming financial stability.
Capex Allocation & Jammu Greenfield Ramp-Up of Innova Captab (FY2027–FY2028)
The enterprise executes a structured capital expenditure plan to scale its Jammu greenfield plant and upgrade R&D centers.
- Jammu Greenfield Project Capex Outlay – Rs 350.00+ crore total investment in Jammu OSD plant
- Jammu Facility Commercial Status – Commercial production commenced; scaling up utilization in FY2027
- R&D Outlay Guidance – 2.5% to 3.0% of annual turnover allocated to formulation R&D
- Planned Annual Group Capex Guidance – Rs 60.00 to Rs 80.00 crore per annum
- Funding Strategy – Funded through IPO fresh issue proceeds and internal cash accruals
Capital expenditure outlays focus on ramping up commercial capacity utilization at the greenfield Jammu facility. Investing 2.5%–3.0% of turnover into formulation R&D supports the development of complex generic product lines.
Strategic Outlook & Management Commentary of Innova Captab (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on CDMO volume growth, Jammu capacity scaling, and export expansion.
- Management targets maintaining a 15.0% to 18.0% annual top-line revenue CAGR over FY2027 and FY2028.
- Consolidated operating EBITDA margins are guided to expand toward the 15.0%–16.0% corridor as Jammu plant scales.
- CDMO customer additions will target expanding supply contracts with top-tier Indian pharmaceutical brand owners.
- International export dispatches to semi-regulated markets are projected to scale toward 15% of total sales.
- Jammu greenfield facility is expected to achieve break-even operating EBITDA in H2 FY2027.
- Capital allocation strategy will prioritize self-funded plant additions while keeping net debt-to-equity below 0.35x.
Management anticipates strong CDMO demand from Indian pharmaceutical majors to support full-year turnover targets. Operational focus centers on scaling Jammu plant capacity utilization, expanding export registrations, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Innova Captab Q1 FY2027 Unaudited Financial Results Disclosures & Stock Exchange Outcomes
- Innova Captab Q1 FY2027 Investor Presentation & Media Release
- Stock Exchange Outcomes & BSE/NSE Filings for Innova Captab
- Corporate Announcements & Board Outcomes for Innova Captab
- Ticker Finology Innova Captab Page
Disclaimer
The information presented above on Innova Captab has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Innova Captab page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.